Teva Entitled To Exclusivity Period For Generic Pravachol – D.C. Court
This article was originally published in The Tan Sheet
Executive Summary
Teva's 180-day marketing exclusivity period for its generic equivalent of Bristol-Myers Squibb's Rx Pravachol (pravastatin) has "neither expired nor even commenced," District of Columbia District Court ruled Oct. 21
You may also be interested in...
Pravachol Exclusivity Case Remanded To FDA By Appeals Court
FDA needs to develop policy clarifying how the voluntary dismissal of a patent litigation proceeding impacts a generic drug maker's 180-day exclusivity period, according to a D.C. federal appeals court decision issued March 16
Pravachol Exclusivity Case Remanded To FDA By Appeals Court
FDA needs to develop policy clarifying how the voluntary dismissal of a patent litigation proceeding impacts a generic drug maker's 180-day exclusivity period, according to a D.C. federal appeals court decision issued March 16
Pravachol Exclusivity Case Remanded To FDA By Appeals Court
FDA needs to develop policy clarifying how the voluntary dismissal of a patent litigation proceeding impacts a generic drug maker's 180-day exclusivity period, according to a D.C. federal appeals court decision issued March 16